Search results
Results from the WOW.Com Content Network
The risk is considerably higher for extractions in the mandible (lower jaw) than other areas of the mouth, and the risk increases if you have been taking it for four or more years [12] Although this side effect is uncommon (0.4-1.6% for oral alendronic acid), it occurs primarily in patients being administered intravenous bisphosphonates, with ...
Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral ...
This type of drug has a high affinity for hydroxyapatite [28] and stays in bone tissue for a long period of time, [29] with alendronate, it has a half-life of approximately ten years. [30] The risk of a patient having MRONJ after discontinuing this medication is unknown. [30]
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
It’s recommended that adults over 50 get the two-dose Shingrix vaccine, which is given between two and six months apart, Dr. Yoon says. ... Research shows that the vaccine is most effective in ...
the dose at which toxicity occurs in 50% of cases. LD Lethal Dose the dose at which death occurs in 50% of cases. [6]: 73 [7] [8] TI Therapeutic Index a quantitative measurement of the relative safety of a drug by comparison of the amount of a therapeutic agent that causes toxicity to the amount that causes the therapeutic effect [1]
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels).
The maximum tolerable dose (MTD) information is necessary to be able to design such groups and therefore dose-ranging studies are usually designed after the availability of MTD information. [1] The main goal of a dose-ranging study is to estimate the response vs. dose given, so as to analyze the efficacy and safety of the drug.